SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Instagram Outage Disrupts Thousands of U.S. Users 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
DURHAM, N.C., March 29, 2016 -- In the release issued earlier today by Argos Therapeutics (Nasdaq:ARGS), please note that the "Selected Third Quarter 2015 Financial Results" header should be "Selected Fourth Quarter and Full-Year 2015 Financial Results." All other information in the press release remains the same.
Media contacts: Adam Daley Berry & Company Public Relations 212-253-8881 [email protected] Investor contact: John Menditto Argos Therapeutics, Inc. 919-908-0687 [email protected]
